Muggia FM - Search Results

1

New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins.

Muggia FM, Russell CA. Muggia FM, et al. Cancer. 1991 Jan 1;67(1 Suppl):225-30. doi: 10.1002/1097-0142(19910101)67:1+<225::aid-cncr2820671304>3.0.co;2-6. Cancer. 1991. PMID: 1984824 Review.

2

Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans.

Shani J, Bertram J, Russell C, Dahalan R, Chen DC, Parti R, Ahmadi J, Kempf RA, Kawada TK, Muggia FM, et al. Shani J, et al. Among authors: muggia fm. Cancer Res. 1989 Apr 1;49(7):1877-81. Cancer Res. 1989. PMID: 2924326

3

Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.

Turrill M, Spicer DV, Kelley AS, Herman RL, Russell CA, Muggia FM. Turrill M, et al. Among authors: muggia fm. Cancer Invest. 1995;13(2):160-4. doi: 10.3109/07357909509011685. Cancer Invest. 1995. PMID: 7874569 Clinical Trial.

4

Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.

Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J, Curtin J, Morrow CP. Muggia FM, et al. Gynecol Oncol. 1993 Aug;50(2):232-8. doi: 10.1006/gyno.1993.1198. Gynecol Oncol. 1993. PMID: 8375739

5

Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography.

Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP, Curtin J, Schlaerth J. Muggia FM, et al. Ann Oncol. 1992 Feb;3(2):149-54. doi: 10.1093/oxfordjournals.annonc.a058132. Ann Oncol. 1992. PMID: 1606086 Free article.

6

Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.

Uziely B, Groshen S, Jeffers S, Morris M, Russell C, Roman L, Muderspach L, Muggia F. Uziely B, et al. Ann Oncol. 1994 Nov;5(9):827-33. doi: 10.1093/oxfordjournals.annonc.a059012. Ann Oncol. 1994. PMID: 7848885 Free article. Clinical Trial.

7

Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.

Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, Jeffers S, Sorich J, Leichman L, Beller U, et al. Muggia FM, et al. Cancer Chemother Pharmacol. 1991;28(4):241-50. doi: 10.1007/BF00685529. Cancer Chemother Pharmacol. 1991. PMID: 1831736

8

MDR1 gene expression in primary and advanced breast cancer.

Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF. Yang X, et al. Lab Invest. 1999 Mar;79(3):271-80. Lab Invest. 1999. PMID: 10092063

9

Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.

Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, Morrow CP, Roman L, Leichman CG, Chan KK. Israel VK, et al. Among authors: muggia fm. Cancer Chemother Pharmacol. 1995;37(1-2):32-8. doi: 10.1007/BF00685626. Cancer Chemother Pharmacol. 1995. PMID: 7497594 Clinical Trial.

10

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.

Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM. Safra T, et al. Among authors: muggia fm. Cancer. 2001 Jan 1;91(1):90-100. Cancer. 2001. PMID: 11148564 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

552 results

Search Page

Filters